Interestingly, the child with KMT2A-rearranged infant AML achieved a molecular CR after salvage therapy with Vyxeos plus crenolanib. This child was successfully bridged to a second HSCT and remains in remission one year after the start of his compassionate use crenolanib....FLT3 status....FLT3 A848P....co-occuring mutations....KMT2A-MLLT3....CR with full count recovery, MRD negative, PET negative, achieved CR, haplo HSCT in 9mths ago, In continued remission of all treatment.